Health & Fitness
Mon, September 17, 2012
BEDMINSTER, N.J.--([ BUSINESS WIRE ])--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is scheduled to present at the Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 12, 2012 at 1:00 p.m. ET and the ThinkEquity 9th Annual Growth Conference on Thursday, September 13, 2012 at 11:00 a.m. ET. Presentations will be available as live webcasts with replays available approximately three hours after the presentations have concluded. Interested parties may access the webcast from the investorsa calendar of events page on the NPS website at [ http://www.npsp.com/page/calendar ].
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. NPS is advancing two late-stage registration programs. A New Drug Application is undergoing FDA review for Gattex (teduglutide) as a treatment for adult short bowel syndrome (SBS) and a Phase 3 registration study has been completed for Natparaa" (recombinant human parathyroid hormone (rhPTH [1-84]) in adult hypoparathyroidism. NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Nycomed (acquired by Takeda Pharmaceutical Company Limited).
